Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
暂无分享,去创建一个
M. Knopp | G. van Kaick | H. Schlemmer | P. Bachert | A. Dietz | H. Weidauer | M. Wannenmacher | M. Becker | B. Vanselow | V. Rudat | P. Wollensack | I. Zuna
[1] M. Knopp,et al. Radiochemotherapy in Head and Neck Carcinoma during Simultaneous Alterations of Intratumoral Pharmacokinetics of 5-Fluorouracil , 1999 .
[2] P. Bachert. PHARMACOKINETICS USING FLUORINE NMR IN VIVO , 1998 .
[3] P. Bachert,et al. Monitoring local disposition kinetics of carboplatin in vivo after subcutaneous injection in rats by means of 195Pt NMR. , 1998, Journal of magnetic resonance.
[4] Chakravarthy,et al. Radiation Therapy and 5-Fluorouracil in Pancreatic Cancer. , 1997, Seminars in radiation oncology.
[5] Rich. Irradiation Plus 5-Fluorouracil: Cellular Mechanisms of Action and Treatment Schedules. , 1997, Seminars in radiation oncology.
[6] Tepper,et al. Fluoropyrimidine-Radiation Interactions in Cells and Tumors. , 1997, Seminars in radiation oncology.
[7] Fu. Radiation Therapy With 5-fluorouracil in Head and Neck Cancer. , 1997, Seminars in radiation oncology.
[8] R. James. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin , 1996, The Lancet.
[9] C. Branch,et al. Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. , 1996, International journal of radiation oncology, biology, physics.
[10] J. Robertson,et al. Current status of radiation sensitization by fluoropyrimidines. , 1995, Oncology.
[11] J R Griffiths,et al. Proton NMR Observation of the Antineoplastic Agent Iproplatin In Vivo by Selective Multiple Quantum Coherence Transfer (Sel‐MQC) , 1995, Magnetic resonance in medicine.
[12] H. Wieand,et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. , 1994, The New England journal of medicine.
[13] C. Presant,et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response , 1994, The Lancet.
[14] W. J. Lorenz,et al. Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma. , 1994, Magnetic resonance imaging.
[15] V. R. McCready,et al. The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-α using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study , 1993 .
[16] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.
[17] J. Glickson,et al. Tumor bioenergetics and blood flow in RIF‐1 murine tumors treated with 5‐fluorouracil , 1991, Magnetic resonance in medicine.
[18] P. Barker,et al. Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[19] W. J. Lorenz,et al. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy. , 1990, Radiology.
[20] J. Griffiths,et al. 19F MRS studies of fluoropyrimidine chemotherapy. A review , 1989, NMR in biomedicine.
[21] J R Griffiths,et al. Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation. , 1989, International journal of radiation oncology, biology, physics.
[22] H. Pinedo,et al. Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Herrmann,et al. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. , 1988, Cancer research.
[24] S. Strother,et al. [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] W Wolf,et al. Fluorine-19 NMR spectroscopic studies of the metabolism of 5-fluorouracil in the liver of patients undergoing chemotherapy. , 1987, Magnetic resonance imaging.
[26] J. Jacobs,et al. A randomized trial of cisplatin (CACP) + 5‐fluorouracil (5‐FU) infusion and CACP + 5‐FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck , 1985, Cancer.
[27] R. Diasio,et al. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells. , 1985, Cancer research.
[28] J. Griffiths,et al. 5-fluorouracil metabolism monitored in vivo by 19F NMR. , 1984, British Journal of Cancer.